Le Lézard
Classified in: Health, Business
Subjects: SVY, ECO, ACC

InDex Pharmaceuticals Holding AB (publ) Publishes Annual Report for 2016


STOCKHOLM, April 27, 2017 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2016. The Annual Report (in the Swedish language) is attached as a PDF and is available on the company's website, www.indexpharma.com.

The printed Annual Report is mailed to shareholders and other stakeholders who specifically request it. Send request to [email protected], or by mail to InDex Pharmaceuticals Holding AB (publ), Tomtebodavägen 23a, 171 77 Stockholm.

For more information:
Peter Zerhouni
CEO
Phone: +46-8-508-847-35
E-mail: [email protected]

InDex Pharmaceuticals in brief 

InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company's foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The company's shares are traded on Nasdaq First North Stockholm. Redeye AB is the company's Certified Adviser. For more information, please visit www.indexpharma.com 

Publication

This information is information that InDex Pharmaceuticals Holding AB (publ) is obliged to make public pursuant to the Swedish Securities Market Act. The information was submitted for publication through the agency of the contact person set out above at 8:00 CET on April 27, 2017.

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/index-pharmaceuticals/r/index-pharmaceuticals-holding-ab--publ--publishes-annual-report-for-2016,c2251262

The following files are available for download:

http://mb.cision.com/Main/9612/2251262/664916.pdf

InDex Pharmaceuticals Holding AB Annual Report 2016 (in Swedish)

http://mb.cision.com/Public/9612/2251262/9799389df47913d0.pdf

PR InDex Annual Report 2016 eng final


These press releases may also interest you

at 08:03
The American Red Cross celebrates The Church of Jesus Christ of Latter-day Saints, headquartered in Salt Lake City, for its substantial donation of $7.35 million. The gift will help purchase blood equipment and biomedical emergency vehicles and will...

at 08:00
Bidpath Inc., a leading provider of global online auction software, proudly announces the launch of AuctionPay, a cutting-edge payments platform designed to revolutionize auction payments. With a focus on efficiency, security, and user-centric...

at 08:00
SC Ventures, Standard Chartered's innovation, fintech investment and ventures arm, is leading a ?12 million (USD $13 million) Series A round for distributed cloud provider Hive, to increase access to sustainable, high-powered computing resources for...

at 08:00
Callon Petroleum Company ("Callon" or the "Company") today announced the expiration and final tender results of its previously announced cash tender offers (the "Offers") for any and all of its 8.000% Senior Notes due 2028 (the "2028 Notes") and any...

at 08:00
The parties in Severa, et al. v. Solvay Specialty Polymers USA, LLC, et al., announce that Judge Noel Hillman of the United States District Court for the District of New Jersey has preliminarily approved a class action settlement. The hearing on...

at 08:00
PassPort Technologies, Inc. (PPTI), based in San Diego, a clinical-stage drug and medical device development company, today announced positive interim results from the Phase 1 (Part A) clinical trial of Zolmitriptan PassPort® utilizing its...



News published on and distributed by: